APA (7th ed.) Citation

Jiang, S., Li, X., Xue, W., Xia, S., Wang, J., Sai, Y., . . . Su, W. (2024). Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies. Frontiers in pharmacology, 15, 1392209. https://doi.org/10.3389/fphar.2024.1392209

Chicago Style (17th ed.) Citation

Jiang, Shuwen, Xiangkun Li, Weifang Xue, Sumei Xia, Jian Wang, Yang Sai, Guangxiu Dai, and Weiguo Su. "Preclinical Pharmacokinetic Characterization of Amdizalisib, a Novel PI3Kδ Inhibitor for the Treatment of Hematological Malignancies." Frontiers in Pharmacology 15 (2024): 1392209. https://doi.org/10.3389/fphar.2024.1392209.

MLA (9th ed.) Citation

Jiang, Shuwen, et al. "Preclinical Pharmacokinetic Characterization of Amdizalisib, a Novel PI3Kδ Inhibitor for the Treatment of Hematological Malignancies." Frontiers in Pharmacology, vol. 15, 2024, p. 1392209, https://doi.org/10.3389/fphar.2024.1392209.